BioPharma Resources

Drug Trial Radar · NCT07334886

A Study of [14C]Ulonivirine ([14C]MK-8507) in Healthy Adults (MK-8507-006)

A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Ulonivirine in Healthy Adults

Last checked: Nov 19, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Sep 17, 2025

Primary completion

Nov 11, 2025

Study completion Nov 11, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jan 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this study is to learn how \[14C\]ulonivirine moves through a healthy person's body over time. Researchers will study how \[14C\]ulonivirine is absorbed by the body, broken down by the body, and how it leaves the body.

Conditions

  • Healthy

Interventions

  • [14C]UlonivirineDrug

    Oral Solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative Percentage of Total Radioactivity Recovered (FE) from Urine and FecesTime frame: At designated timepoints (up to approximately 5 weeks postdose)
  2. FE from UrineTime frame: At designated timepoints (up to approximately 5 weeks postdose)
  3. FE from FecesTime frame: At designated timepoints (up to approximately 5 weeks postdose)
  4. Cumulative Amount of Radioactivity Recovered from UrineTime frame: At designated timepoints (up to approximately 5 weeks postdose)
  5. Percent of Total Radioactive Dose Recovered from UrineTime frame: At designated timepoints (up to approximately 5 weeks postdose)
  6. Cumulative Amount of Radioactivity Recovered from FecesTime frame: At designated timepoints (up to approximately 5 weeks postdose)
  7. Percent of Total Radioactive Dose Recovered from FecesTime frame: At designated timepoints (up to approximately 5 weeks postdose)
  8. Plasma Ulonivirine: Area Under the Concentration-Time Curve from Time 0 to Time of the Last Concentration (AUC0-last)Time frame: At designated timepoints (up to approximately 2 weeks postdose)
  9. Plasma Ulonivirine: Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf)Time frame: At designated timepoints (up to approximately 2 weeks postdose)
  10. Plasma Ulonivirine: Maximum Observed Concentration (Cmax)Time frame: At designated timepoints (up to approximately 2 weeks postdose)
  11. Plasma Ulonivirine: Concentration at 168 Hours Postdose (C168)Time frame: At approximately 1 week postdose
  12. Plasma Ulonivirine: Terminal Half-life (t1/2)Time frame: At designated timepoints (up to approximately 2 weeks postdose)
  13. Plasma Ulonivirine: Time of Maximum Observed Concentration (Tmax)Time frame: At designated timepoints (up to approximately 2 weeks postdose)
  14. Ratio of Ulonivirine to Total Plasma Radioactivity: AUC0-last (ulonivirine)/ AUC0-last (total radioactivity)Time frame: At designated timepoints (up to approximately 5 weeks postdose)
  15. Plasma Total Radioactivity: AUC0-lastTime frame: At designated timepoints (up to approximately 5 weeks postdose)
  16. Plasma Total Radioactivity: AUC0-infTime frame: At designated timepoints (up to approximately 5 weeks postdose)
  17. Plasma Total Radioactivity: CmaxTime frame: At designated timepoints (up to approximately 5 weeks postdose)
  18. Plasma Total Radioactivity: C168Time frame: At approximately 1 week postdose
  19. Plasma Total Radioactivity: t1/2Time frame: At designated timepoints (up to approximately 5 weeks postdose)
  20. Plasma Total Radioactivity: TmaxTime frame: At designated timepoints (up to approximately 5 weeks postdose)
  21. Total Number of Metabolites in Plasma that Represent at least 10% of the Dose of RadioactivityTime frame: At designated timepoints (up to approximately 5 weeks postdose)
  22. Total Number of Metabolites in Urine that Represent at least 10% of the Dose of RadioactivityTime frame: At designated timepoints (up to approximately 5 weeks postdose)
  23. Total Number of Metabolites in Feces that Represent at least 10% of the Dose of RadioactivityTime frame: At designated timepoints (up to approximately 5 weeks postdose)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fortea CRU Madison (Site 002)

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.